Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
Public ClinicalTrials.gov record NCT02283268. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Prospective, Multicenter Study to Evaluate Efficacy and Safety of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Elective Surgical Procedures in Subjects With Severe Von Willebrand Disease
Study identification
- NCT ID
- NCT02283268
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- Recombinant von Willebrand Factor (rVWF) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2015
- Primary completion
- Jul 5, 2016
- Completion
- Jul 5, 2016
- Last update posted
- May 18, 2021
2015 – 2016
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Hemophilia & Thrombosis Center | Aurora | Colorado | 80045 | — |
| University of Miami, Jackson Memorial Hospital | Miami | Florida | 33136 | — |
| Georgia Regents University | Augusta | Georgia | 30912 | — |
| John Hopkins University | Baltimore | Maryland | 21205 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Rutgers - Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | — |
| Duke University Medical Center | Durham | North Carolina | 27705 | — |
| Case Western Reserve University Hospital | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Medical University of South Carolina (MUSC) | Charleston | South Carolina | 29425 | — |
| Blood Center of South East Wisconsin | Milwaukee | Wisconsin | 53233 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02283268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02283268 live on ClinicalTrials.gov.